Weed, Inc. (BUDZ): Shareholders' Equity
-$688.4K
As of 2025-12-31
-$939.2K
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$688.4K | n/m | 2026-04-08, Balance as of period end |
| 2024-12-31 | -$221.0K | n/m | 2026-04-08, Balance as of period end |
| 2023-12-31 | $255.3K | +50.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $169.8K | -72.5% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $617.5K | -30.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $881.7K | -26.5% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $1.20M | -56.6% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $2.76M | +666.7% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $360.2K | n/a | 2019-04-16, Balance as of period end |
| No annual figure between 2011-12-31 and 2017-12-31. | |||
| 2011-12-31 | -$110.8K | n/m | 2012-04-16, Balance as of period end |
| 2010-12-31 | -$7.3K | n/a | 2012-04-16, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Weed, Inc. (BUDZ) | 2025-12-31 | -$688.4K | n/m |
| NRC Health (NRC) | 2025-12-31 | $13.99M | -55.3% |
| Incyte Corp (INCY) | 2025-12-31 | $5.17B | +49.9% |
| Icon PLC (ICLR) | 2025-12-31 | $9.19B | -2.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.17B | -8.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $171.49M | -16.9% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | -$1.16M | n/m |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $6.63B | +9.3% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $3.09M | -6.7% |
Compare BUDZ, NRC, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗